Skip to content
Dose Brief
Menu
Head-to-head · Brief Score

Ondra Health vs HealthRX

Two GLP-1 desks, one scoreboard. We put Ondra Health and HealthRX head-to-head on the published Brief Score — the same six factors, scored the same way, no pay-to-win placement.

Higher Brief ScoreNo. 8 · Grade B+

Ondra Health

Visit Ondra Health Full brief →
vs
No. 17 · Grade B

HealthRX

Visit HealthRX Full brief →

The verdict

Ondra Health takes this head-to-head.

Ondra Health scores 87 to 86 on our six-factor Brief Score — A rare combination of a rock-bottom $93 semaglutide, brand-name access, LegitScript certification and all-50-state reach.

That doesn't make HealthRX a bad call — it's best for readers who want an accredited, physician-supervised program with a needle-free oral tablet option on either molecule — and value a legitscript trust signal, while accepting that some tiers are company-stated. Weigh the six factors below against your own priorities before you decide.

Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Brief Score.

Factor by factor

Both desks scored on the six published Brief Score factors. The higher score in each row is marked. See the methodology.

Price Stability
88
85
Supply Reliability
86
85
Transparency
88
83
Access Breadth
90
91
Clinical Oversight
88
89
Track Record
82
81
Ondra HealthBrief Score 87 · 86HealthRX

Price, coverage & the tracker

Ondra HealthHealthRX
Brief Score87/100 (B+)86/100 (B)
Semaglutide$93/mo$189/mo
Tirzepatide$166/mo$349/mo
CoverageAll 50 statesNot publicly listed
Brand-name accessYesYes
Oral / sublingualInjection onlyYes
On the trackerStableprice stableStableprice stable

Ondra Health: $93 sema / $166 tirz — the lowest accredited nationwide line we track; brand access + LegitScript.

HealthRX: Company-stated tiers held flat this cycle; the LegitScript badge and a rare oral GLP tablet are the draw, but some tiers are self-reported rather than checkout-verified.

Not sold on either?

CoreAge Rx tops the whole board at 94/100.

The steadiest desk on the board: one flat, no-step-up price on both molecules, nationwide, and it hasn't moved.

Keep comparing

Pricing, states and access reflect each provider's public disclosures at last review; the Brief Score is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.